Latest News
DualityBio reports China NMPA acceptance of BLA for T-Pam for treatment of unresectable or metastatic HER2-positive breast cancer
10 April 2026 - Chinese biopharmaceutical company DualityBio (HK:9606) announced on Thursday that the Biologics License Application (BLA) for the investigational antibody-drug conjugate (ADC) trastuzumab pamirtecan ('T-Pam', also known as D...
Gan & Lee and JW Pharmaceutical sign licensing deal for Bofanglutide Injection in South Korea
10 April 2026 - Chinese pharmaceutical company Gan & Lee Pharmaceuticals (SSE:603087) announced on Thursday that it has entered into an exclusive licensing agreement with JW Pharmaceutical, a pharmaceutical company in South Korea.Under the agreem...
DifGen and Apotex report FDA approval of generic Nintedanib Soft Gel Capsules
10 April 2026 - DifGen Pharmaceuticals LLC, a US-based specialty generic pharmaceutical company, announced on Thursday that its Canadian partner, Apotex Inc, has received final approval from the US Food and Drug Administration (FDA) for its Abbreviat...
Oricell Therapeutics completes USD110m pre-IPO financing
10 April 2026 - Oricell Therapeutics Holdings Limited, a clinical-stage biotechnology company developing next-generation cell therapies for oncology and immunology, announced on Thursday the cumulative closing of a pre-IPO financing round in excess o...
ArkBio completes first cohort dosing in Australian phase I trial of antiviral drug-Fc conjugate for influenza
10 April 2026 - Chinese biopharmaceutical company Shanghai Ark Biopharmaceutical Co Ltd. (ArkBio) announced on Thursday that the first cohort of healthy volunteers has been dosed in a phase I clinical trial of AK0406, a novel long-acting antiviral dr...